DUAL INHIBITION OF EZH2 AND HDAC IS SYNERGISTIC IN EZH2 DYSREGULATED LYMPHOMAS

Abstract

Introduction: EZH2 is the catalytic subunit of the PRC2 complex and induces tri‐methylation of H3K27. Activating mutations in EZH2 are found in 7–12% of FL and 22% of GC‐DLBCL. Mutations in the histone acetyltransferases (HATs) CBP and p300 have been implicated in B‐ and T‐cell lymphomas. Given the presence of EZH2 and HAT dysregulation in B‐cell lymphomas, we hypothesized that EZH2 and HDAC inhibitors would be synergistic.